Streetbeat News

DRMAW

Dermata Therapeutics, Inc.

http://www.dermatarx.com

Industry

Biotechnology

Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, a once-weekly topical product that is under clinical development for the treatment of acne vulgaris, psoriasis vulgaris, and papulopustular rosacea. It is also developing DMT410 for the treatment of hyperhidrosis and aesthetic conditions. The company was founded in 2014 and is headquartered in San Diego, California.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Dermata Therapeutics has entered into agreements for the immediate exercise of certain warrants to purchase up to 516,336 shares of its common stock at a reduced exercise price of $5.16 per share. The closing of the offering is expected around May 21, 2024, with H.C. Wainwright & Co. acting as the exclusive placement agent.

Portfolio Pulse from Benzinga Newsdesk

May 17, 2024 | 12:36 pm

Trading halt status for DRMAW was updated at 9:00:00 AM ET. The quotation resumption times and related news are expected to follow.

Portfolio Pulse from Benzinga Newsdesk

May 16, 2024 | 1:00 pm

Dermata Therapeutics, Inc. (NASDAQ:DRMAW) saw its shares surge in after-hours trading following the announcement of a new patent issued in Japan for its DMT410 program, aimed at treating hyperhidrosis. The patent marks the first for DMT410 and leverages Dermata's Spongilla technology for topical delivery of botulinum toxin. The company's CEO highlighted the patent's validation of the novel concept and potential treatment opportunities for various forms of hyperhidrosis. Shares of Dermata increased by 96.7% to $1.20 in after-hours trading.

Portfolio Pulse from Ryan Gustafson

January 04, 2024 | 10:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.